1. The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer.
- Author
-
Paul, Evan D., Huraiová, Barbora, Valková, Natália, Matyasovska, Natalia, Gábrišová, Daniela, Gubová, Soňa, Ignačáková, Helena, Ondris, Tomáš, Gala, Michal, Barroso, Liliane, Bendíková, Silvia, Bíla, Jarmila, Buranovská, Katarína, Drobná, Diana, Krchňáková, Zuzana, Kryvokhyzha, Maryna, Lovíšek, Daniel, Mamoilyk, Viktoriia, Mancikova, Veronika, and Vojtaššáková, Nina
- Subjects
FLUORESCENCE in situ hybridization ,MEDICAL sciences ,ANTIBODY-drug conjugates ,CYCLIN-dependent kinase inhibitors ,BREAST cancer - Abstract
Current assays fail to address breast cancer's complex biology and accurately predict treatment response. On a retrospective cohort of 1082 female breast tissues, we develop and validate mFISHseq, which integrates multiplexed RNA fluorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, unbiased whole transcriptome profiling, and explicitly quantifies intratumoral heterogeneity. Here we show mFISHseq has 93% accuracy compared to immunohistochemistry. Our consensus subtyping and risk groups mitigate single sample discordance, provide early and late prognostic information, and identify high risk patients with enriched immune signatures, which predict response to neoadjuvant immunotherapy in the multicenter, phase II, prospective I-SPY2 trial. We identify putative antibody-drug conjugate (ADC)-responsive patients, as evidenced by a 19-feature T-DM1 classifier, validated on I-SPY2. Deploying mFISHseq as a research-use only test on 48 patients demonstrates clinical feasibility, revealing insights into the efficacy of targeted therapies, like CDK4/6 inhibitors, immunotherapies, and ADCs. The authors develop and validate mFISHseq, a spatially informed assay that tackles several unmet needs in breast cancer, including discordance in molecular subtyping and prognostic risk and identification of biomarkers predicting response to immunotherapies and antibody-drug conjugates. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF